Masimo Corporation (NASDAQ:MASI) – Equities research analysts at William Blair boosted their FY2017 EPS estimates for shares of Masimo Corporation in a research report issued to clients and investors on Wednesday. William Blair analyst B. Weinstein now expects that the medical equipment provider will post earnings of $2.96 per share for the year, up from their prior estimate of $2.80. William Blair also issued estimates for Masimo Corporation’s Q1 2018 earnings at $0.63 EPS, Q2 2018 earnings at $0.65 EPS, Q3 2018 earnings at $0.64 EPS, Q4 2018 earnings at $0.61 EPS and FY2018 earnings at $2.52 EPS.
Masimo Corporation (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.17. The firm had revenue of $193.69 million for the quarter, compared to the consensus estimate of $189.01 million. Masimo Corporation had a return on equity of 22.89% and a net margin of 45.83%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.52 earnings per share.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/02/fy2017-earnings-forecast-for-masimo-corporation-issued-by-william-blair-masi.html.
Several other brokerages have also issued reports on MASI. BidaskClub lowered shares of Masimo Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Masimo Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. Stifel Nicolaus restated a “buy” rating and set a $108.00 price target (up previously from $105.00) on shares of Masimo Corporation in a research note on Thursday, August 3rd. BTIG Research upgraded shares of Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research note on Monday, August 14th. Finally, Roth Capital raised their price target on shares of Masimo Corporation from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, July 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $97.00.
Several hedge funds have recently modified their holdings of MASI. BlackRock Inc. increased its stake in shares of Masimo Corporation by 7.5% during the 2nd quarter. BlackRock Inc. now owns 7,915,230 shares of the medical equipment provider’s stock worth $721,710,000 after purchasing an additional 550,995 shares during the last quarter. Koch Industries Inc. grew its stake in Masimo Corporation by 5,053.7% in the 2nd quarter. Koch Industries Inc. now owns 443,939 shares of the medical equipment provider’s stock valued at $439,000 after buying an additional 435,325 shares in the last quarter. State Street Corp grew its stake in Masimo Corporation by 42.8% in the 1st quarter. State Street Corp now owns 1,401,516 shares of the medical equipment provider’s stock valued at $130,704,000 after buying an additional 419,767 shares in the last quarter. Acadian Asset Management LLC grew its stake in Masimo Corporation by 28.0% in the 2nd quarter. Acadian Asset Management LLC now owns 1,791,597 shares of the medical equipment provider’s stock valued at $163,356,000 after buying an additional 392,410 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Masimo Corporation by 76.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 802,698 shares of the medical equipment provider’s stock valued at $73,191,000 after buying an additional 347,360 shares in the last quarter. Institutional investors own 82.96% of the company’s stock.
In other news, Director Sanford Fitch sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $87.25, for a total transaction of $959,750.00. Following the completion of the sale, the director now owns 72,249 shares in the company, valued at approximately $6,303,725.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 16.60% of the company’s stock.
About Masimo Corporation
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.